A potential role for activated HER-2 in prostate cancer

Seminars in Oncology

Volumn 27, Issue 6 SUPPL. 11, 2000, Pages 76-83

  Agus, D B ^a   Akita, R W ^a   Fox, W D ^a   Lofgren, J A ^a   Higgins, B ^a   Maiese, K ^a   Scher, H I ^a   Sliwkowski, M X ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; TYROSINE KINASE RECEPTOR;

ANIMAL EXPERIMENT; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL GROWTH; CONFERENCE PAPER; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LIGANDS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2;

EID: 0034474313     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. The biology of human epidermal growth factor receptor 2
2. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands
3. ErbB receptors and EGF-like ligands: Cell lineage determination and oncogenesis through combinatorial signaling
4. The erbB3 gene product is a receptor for heregulin
5. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity
6. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin
7. Transformation of N1H 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2
8. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor
9. Requirement for neuregulin receptor erbB2 in neural and cardiac development
10. The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4
11. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
12. Alternative intracellular routing of ErbB receptors may determine signaling potency
13. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers
14. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB2 and epidermal growth factor receptors
15. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas
16. Mechanism of activation of a human oncogene
17. The neu oncogene encodes an epidermal growth factor receptor-related protein
18. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
19. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer
20. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
21. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies
22. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diaminedichloroplatinum against human breast and ovarian tumor cell lines
23. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists
24. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
25. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth
26. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
27. Development of trastuzumab
28. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
29. Concurrent administration of anti-HER2 monoclonal antibody and firstline chemotherapy for HER2-overexpressing metastatic breast cancer: A phase III, multinational, randomized, controlled trial
30. Neu receptor dimerization [letter]
31. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation
32. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
33. Inhibitory Fc receptors modulate in vivo cyroroxicity against tumor targets
34. Therapeutic application of anti-growth factor receptor antibodies
35. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family
36. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness
37. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4
38. EGF receptor signaling in prostate morphogenesis and tumorigenesis
39. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms
40. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells
41. Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor
42. Growth factors in steroid-responsive prostatic tumor cells
43. A potential autocrine loop between heregulin-alpha and erbB-3 receptor in human prostatic adenocarcinoma
44. g-Heregulin: A novel heregulin isoform that is an autocrine growth factor for the human breast tumor cell line, MDA-MB-175
45. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
46. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
47. CWR22: Androgen-dependent xenograft model derived from a primary human prostatic carcinoma
48. CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar
49. Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence
50. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest
51. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation
52. Androgen-repressed phenotype in human prostate cancer
53. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models